Abstract

This study examined the feasibility of using interleukin-2 as a vaccine adjuvant to enhance specific immunity in the bovine mammary gland. In trial 1, cows were immunized by intramammary infusion of keyhole limpet hemocyanin with either saline (n=3) or interleukin-2 (n=3) as adjuvants. In trial 2, cows were immunized by intramuscular injection near the supramammary lymph node with keyhole limpet hemocyanin in conjunction with saline (n=4). Freund's incomplete adjuvant (n=4). or interleukin-2 (n=4). Local immunization with interleukin-2 as an adjuvant significantly increased antibody titers in milk over preimmunization levels and levels in saline-treated cows. The use of Freund's incomplete adjuvant and interleukin-2 as adjuvants in cows that were immunized systemically enhanced both sera and lacteal antibodies to keyhole limpet hemocyanin. However, cows that were administered interleukin-2 responded more quickly than those given Freund's incomplete adjuvant. Only those cows that received interleukin-2 as an adjuvant demonstrated significant increases in blood lymphocyte proliferation to keyhole limpet hemocyanin, pokeweed mitogen, and interleukin-2. The results of these two trials suggest that immunization with interleukin-2 as an adjuvant may be more effective than Freund's incomplete adjuvant in enhancing specific immunity in the bovine mammary gland and may possibly be an effective adjuvant in mastitis immunization protocols.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.